Citations

Institution: Mayo Clinic Clear

Showing 10 of 108135 citations.

Diagnosis of Takotsubo Cardiomyopathy
Scantlebury, Dawn C. , Prasad, Abhiram , Prasad, Abhiram

Circulation Journal | August 12, 2014 | Volume: 78 | Issue: 9 | Pages: 2129-2139

10.1253/circj.cj-14-0859 | PMID 25131525 Get It

Spontaneous Coronary Artery Dissection
Alfonso, Fernándo , Rivero, Fernando , Cuesta, Javier , Benedicto, Amparo, Saw, Jacqueline , Gulati, Rajiv , Bastante, Teresa

Circulation Journal | August 12, 2014 | Volume: 78 | Issue: 9 | Pages: 2099-2110

10.1253/circj.cj-14-0773 | PMID 25131524 Get It

Targeting aPKC disables oncogenic signaling by both the EGFR and the proinflammatory cytokine TNFα in glioblastoma
Kusne, Yael , Silva, Eugenio Antonio Carrera , Perry, Anthony S. , Mandell, Edward K., Dietrich, Justin , Errasti, Andrea Emilse , Gibbs, Daniel , Berens, Michael E. , Loftus, Joseph C. , Hulme, Christopher , Aldape, Kenneth , Sanai, Nader , Rothlin, Carla V. , Ghosh, Sourav , Rushing, Elisabeth Jane , Yang, Weiwei , Lu, Zhimin , Berens, Michael E

Science Signaling | August 12, 2014 | Volume: 7 | Issue: 338 | Pages: No page available

10.1126/scisignal.2005196 | PMID 25118327 Get It

Targeting a kinase common to both the EGFR and TNFα signaling pathways may prevent drug resistance in glioblastoma.
Safety and Efficacy of Transition from Inhaled Treprostinil to Parenteral Treprostinil in Selected Patients with Pulmonary Arterial Hypertension
Feldman, Jeremy, Franco, Verónica , Ishizawar, David, Hill, Nicholas S. , Preston, Ioana R. , White, James , Burger, Charles D. , Waxman, Aaron B.

Pulmonary Circulation | August 12, 2014 | Volume: 4 | Issue: 3 | Pages: 456-461

10.1086/677360 | PMID 25621159 Get It

Guidelines for the treatment of pulmonary arterial hypertension (PAH) recommend sequential add‐on therapy for patients who deteriorate or fail to improve clinically. However, it is not known whether these patients also benefit from transitioning from inhaled prostacyclins to parenteral prostacyclins. We sought to characterize PAH patients receiving inhaled treprostinil who were transitioned to parenteral treprostinil. We conducted a multicenter retrospective study at 7 PAH centers and collected reasons, methods, safety, and outcome of patients transitioned from inhaled treprostinil to parenteral treprostinil. Twenty‐six patients with pulmonary hypertension in group 1, 4, or 5 transitioned from inhaled treprostinil to parenteral treprostinil (10 intravenous, 16 subcutaneous). Twenty‐four patients were also on one or two oral therapies. Reasons for transition were clinical deterioration, lack of clinical improvement, and pregnancy (19, 6, and 1 patients, respectively). Transitions occurred in hospital, clinic, or home (17, 7, and 2 patients, respectively). Parenteral infusion was started after the last inhaled treatment at maintenance dose (13 patients), after the inhaled therapy was downtitrated to 18 μg (6 patients), or with an overlap of inhaled downtitration with parenteral uptitration (7 patients). The transition was safe; side effects included symptoms of prostacyclin overdose. Patients were followed for 3–18 months. At 3 months, 8 patients improved, 17 maintained their functional class, and 1 continued to deteriorate. In conclusion, selected PAH patients can be safely transitioned from inhaled treprostinil to parenteral treprostinil using a variety of methodologies in different settings with the expectation that patients will improve or at least remain clinically stable.
Quantification of clonal circulating plasma cells in relapsed multiple myeloma
Morice, William G. , Timm, Michael, Dispenzieri, Angela , Lacy, Martha Q. , Kapoor, Prashant , Kumar, Shaji , Gonsalves, Wilson I. , Morice, William George , Rajkumar, S. Vincent , Gupta, Vinay Kumar , Buadi, Francis K. , Singh, Preet Paul , Gertz, Morie A. , Dispenzieri, Angela

British Journal of Haematology | August 12, 2014 | Volume: 167 | Issue: 4 | Pages: 500-505

10.1111/bjh.13067 | PMID 25113422 Get It

Summary The presence of clonal circulating plasma cells (c PC s) remains a marker of high‐risk disease in newly diagnosed multiple myeloma (MM) patients. However, its prognostic utility in MM patients with previously treated disease is unknown. We studied 647 consecutive patients with previously treated MM seen at the Mayo Clinic, Rochester who had their peripheral blood evaluated for c PC s by multi‐parameter flow cytometry. Of these patients, 145 had actively relapsing disease while the remaining 502 had disease that was in a plateau and included 68 patients in complete remission (CR) and 434 patients with stable disease. Patients with actively relapsing disease were more likely to have clonal c PC s than those in a plateau ( P < 0·001). None of the patients in CR had any clonal c PC s detected. Among patients whose disease was in a plateau, the presence of clonal c PC s predicted for a worse median survival (22 months vs. not reached; P = 0·004). Among actively relapsing patients, the presence of ≥100 c PC s predicted for a worse survival after flow cytometry analysis (12 months vs. 33 months; P < 0·001). Future studies are needed to determine the role of these findings in developing a risk‐adapted treatment approach in MM patients with actively relapsing disease.
Improving the 510(k) FDA Process for Cardiac Troponin Assays: In Search of Common Ground
Apple, Fred S. , Hollander, Judd E. , Wu, Alan H.B. , Jaffe, Allan S. , Jaffe, Allan S.

Clinical Chemistry | August 12, 2014 | Volume: 60 | Issue: 10 | Pages: 1273-1275

10.1373/clinchem.2014.229286 | PMID 25114274 Get It

Troponin Elevations Only Detected With a High‐sensitivity Assay: Clinical Correlations and Prognostic Significance
Korley, Frederick K. , Schulman, Steven P. , Sokoll, Lori J. , DeFilippis, Andrew P. , Stolbach, Andrew , Bayram, Jamil D., Saheed, Mustapha , Omron, Rodney , Fernandez, Christopher , Lwin, A.T., Cai, Stephen S. , Jaffe, Allan S. , Post, Wendy S. , Jaffe, Allan S.

Academic Emergency Medicine | August 11, 2014 | Volume: 21 | Issue: 7 | Pages: 727-735

10.1111/acem.12417 | PMID 25112512 Get It

AbstractObjectivesWith clinical use of high‐sensitivity troponin I (hsTnI), more frequent troponin elevations will occur. However, the burden and implications of these elevations are not well understood. The authors quantified the prevalence of elevated hsTnI in patients presenting with possible acute coronary syndrome (ACS) who do not have elevated troponin with a current generation assay (cardiac troponin I [cTnI]) and determined the association of these newly detected elevations with a composite of all‐cause mortality and subsequent cardiac hospitalization.MethodsThis was a prospective observational study of 808 subjects evaluated for possible ACS and followed for up to 1 year. Troponin values were measured with hsTnI (Abbott Laboratories) and cTnI (Abbott and Beckman Coulter). Cardiac hospitalization was defined as hospitalization for ACS, revascularization, acute heart failure (AHF), or tachy/brady arrhythmia that occurred after the index emergency department (ED) visit or hospital discharge.ResultsForty subjects (5%) were diagnosed with ACS (26 myocardial infarction and 14 unstable angina). On the initial sample, the prevalence of elevated hsTnI among subjects with nonelevated cTnI was 9.2% using a gender‐neutral cutoff (95% confidence interval [CI] = 7.1% to 11.4%) and 11.1% using a gender‐specific cutoff (95% CI = 8.8% to 13.4%). Adjudicated diagnoses for subjects whose initial samples had elevated hsTnI but nonelevated cTnI (gender‐neutral cutoff) were as follows: three (4.6%) ACS, 15 (23.1%) AHF, three (4.6%) volume overload etiology unclear/noncardiac, three (4.6%) cardiac (non‐ACS), and 41 (63.1%) other. Of the 65 patients whose initial samples had hsTnI but nonelevated cTnI, eight developed cTnI elevation on subsequent serial sampling. After traditional cardiovascular risk factors and renal function were adjusted for, subjects with elevated initial hsTnI but nonelevated cTnI (initial and serial sampling) had a higher risk of all‐cause mortality and subsequent cardiac hospitalization than subjects with both nonelevated hsTnI and nonelevated cTnI (hazard ratio [HR] = 1.91, 95% CI = 1.14 to 3.19).ConclusionsOn the initial sample, 9% to 11% of subjects without cTnI elevation had hsTnI elevation. Although the majority of the patients with these newly detected hsTnI elevations did not have ACS, they had a higher risk for all‐cause mortality and subsequent cardiac hospitalization.
Physician Attitudes toward Palliative Care for Patients with Pulmonary Arterial Hypertension: Results of a Cross‐Sectional Survey
Fenstad, Eric R. , Sloan, Jeff A. , Novotny, Paul J. , Durst, Louise A., Frantz, Robert P. , McGoon, Michael D., Swetz, Keith M. , Shanafelt, Tait D. , Frantz, Robert P

Pulmonary Circulation | August 11, 2014 | Volume: 4 | Issue: 3 | Pages: 504-510

10.1086/677365 | PMID 25621164 Get It

Pulmonary arterial hypertension (PAH) is a chronic, symptomatic, life‐threatening illness; however, it is complex, with variable expression regarding impact on quality of life (QOL). This study investigated attitudes and comfort of physicians regarding palliative care (PC) for patients with PAH and explored potential barriers to PC in PAH. An internet‐based, mixed‐methods survey was distributed to Pulmonary Hypertension Clinicians and Researchers, a professional organization within the Pulmonary Hypertension Association. Only responses from physicians involved in clinical care of patients with PAH were analyzed. Of 355 clinicians/researchers, 79 (22%) returned surveys, including 76 (21%) providers involved in clinical care. Responding physicians were mainly pulmonologists (67%), practiced in university/academic medical centers (89%), had been in practice a mean of 12 ± 7 years, cared for a median of 100 PAH patients per year, and reported a high level of confidence in managing PAH (87%), advanced PAH‐specific pharmacologic interventions (95%), and end‐of‐life care (88%). Smaller proportions were comfortable managing pain (62%) and QOL issues (78%). Most physicians (91%) reported utilizing PC consultation at least once in the prior year, primarily in the setting of end‐of‐life/active dying (59%), hospice referral (46%), or symptomatic dyspnea/impaired QOL (40%). The most frequent reasons for not referring patients to PC included nonapproval by the patient/family (51%) and concern that PC is “giving up hope” (43%). PAH may result in symptoms that impair QOL despite optimal PAH therapy; however, PC awareness and utilization for PAH providers is low. Opportunities may exist to integrate PC into care for PAH patients.
Clinical Reasoning: A 38-year-old woman with childhood-onset weakness
Ghosh, Partha S. , Milone, Margherita

Neurology | August 11, 2014 | Volume: 83 | Issue: 7 | Pages: No page available

10.1212/wnl.0000000000000698 | PMID 25114203 Get It

Translational Research in Acute Central Nervous System Injury
Warner, David S. , James, Michael L. , Laskowitz, Daniel T. , Wijdicks, Eelco F., Wijdicks, Eelco F. M.

JAMA Neurology | August 11, 2014 | Volume: 71 | Issue: 10 | Pages: 1311

10.1001/jamaneurol.2014.1238 | PMID 25111291 Get It